Key result
Escherichia coli endotoxin (LPS) administration in healthy men significantly increased peak plasma NT-proBNP levels compared to placebo (40.7 vs. 16.1 pg/ml; P = 0.023).
Why the study?
Does LPS administration increase plasma NT-proBNP levels in healthy men?
RCT (n=10)
placebo-controlled
randomized
Does LPS administration increase plasma NT-proBNP levels in healthy men?
Absolute Event Rate: 40.7% vs 16.1%
p-value: p=0.023
Systemic infection and inflammation can elevate NT-proBNP levels independently of left ventricular dysfunction, highlighting the need to account for infections when interpreting this biomarker.
Inflammation raises NT-proBNP without LV dysfunction; clinicians must account for infection when interpreting levels, extending non-cardiac confounder evidence.
Circulating levels of B-type natriuretic peptide (BNP) and NH(2)-terminal-proBNP (NT-proBNP) increase in response to volume overload and help in the differential diagnosis of acute heart failure. Elevated plasma BNP levels are observed also in sepsis and do not always correspond to left ventricular dysfunction. Here, we investigated plasma NT-proBNP fluctuations in response to human bacterial endotoxinemia, an experimental model of systemic infection and inflammation. Escherichia coli endotoxin (LPS) (2 ng/kg) was administered to 10 healthy volunteers in a randomized, placebo-controlled, cross-over design. Plasma NT-proBNP, C-reactive protein (CRP), COOH terminal pro-endothelin-1 (CT-proET-1), and midregional-pro-adrenomedullin (MR-proADM) were measured at hourly intervals for 6 h. LPS administration induced a continuous increase in plasma NT-proBNP that reached peak values after 6 h (40.7 +/- 7.9 vs. 16.1 +/- 3.2 pg/ml in placebo days, mean +/- SE; P = 0.023). The profile of changes in NT-proBNP correlated to changes in body temperature (P < 0.001), heart rate (P = 0.005), CRP (P < 0.001), and CT-proET-1 (P = 0.008), but not to blood pressure values. Our results demonstrate that plasma NT-proBNP increases in a model of systemic infection/inflammation in healthy men with normal heart function. This finding emphasizes the necessity to consider concomitant infections when interpreting elevated circulating NT-proBNP concentrations.
No takes yet. Share an insight, caveat, or question.
Vila et al. (2008) conducted an RCT in Healthy (n=10). Escherichia coli endotoxin (LPS) vs. placebo was evaluated on peak plasma NT-proBNP values after 6 h (p=0.023). Escherichia coli endotoxin (LPS) administration in healthy men significantly increased peak plasma NT-proBNP levels compared to placebo (40.7 vs. 16.1 pg/ml; P = 0.023).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: